imipenemrelebaktam
Imipenemrelebaktam is a fixed‑dose intravenous antibiotic combination that includes imipenem, cilastatin, and relebactam. It is marketed as a single product (often referred to as imipenem/cilastatin/relebactam) and is used to treat certain serious infections caused by Gram‑negative bacteria. The cilastatin component inhibits renal dehydropeptidase I to prevent imipenem degradation in the kidney, while relebactam is a β-lactamase inhibitor that protects imipenem from degradation by specific β-lactamases, thereby restoring or enhancing its activity.
The therapy broadens the spectrum of imipenem by countering certain β-lactamases, particularly some class A and
Indications typically include complicated intra‑abdominal infections, complicated urinary tract infections, and hospital-acquired bacterial pneumonia, including ventilator-associated